T1-A
Chambers, sessional
Grand Canal Capital Partners
Internal · 2026-05-10
Investment Intelligence Platform
Irish Dermatology — a structural undersupply,
institutionally addressable.
A 5-year, capital-efficient platform play to capture the structural undersupply of private dermatology services in Ireland through 2–3 consultant-led centres across Dublin, Cork, Waterford, and Galway.
€60–90m
GCCP-addressable
SOM at maturity
SOM at maturity
60,000+
Public OPD
waiting list
waiting list
47 / 82
Consultants vs.
ISF benchmark
ISF benchmark
8–12×
EBITDA exit
multiple range
multiple range
8 case studies
27+ working-knowledge corrections
6 deployable IC-pack one-liners
Source-of-truth: GCCP Dermatology MASTER repo · v0.2
v0.2 · Living document
01 · Investment Thesis
Ireland is operating at less than half the dermatology supply ratio it requires.AI-DRAFT
The gap is not closing — it is widening. Demand grew 55% from 2019–2024; supply grew only 28%. The capacity deficit is the private sector.
Active consultants
47vs. ISF 82
Ireland operates at <58% of benchmark ratio
Public waiting list
60k+ patients
Some patients waiting up to 3 years
Private waits
12–24months
Insured patients at Blackrock, Mater Private
Single-clinic proof
€10–14m
Ryan/Ralph Institute revenue at ~40k visits
The five-line thesis
A structurally undersupplied private dermatology market, a binding consultant-supply constraint that favours organised platforms over solo practitioners, a precedent-setting single-clinic operator (the Institute of Dermatologists), an exit pathway validated by UK/EU comparables at 8–12× EBITDA, and a regulatory window that closes for disciplined operators within 18–30 months.
Why GCCP can win
- We can fund and build medical-grade real estate; this is core competence.
- We can structure PropCo/OpCo and align consultants through equity — analogous to our hotel operator model.
- We have LP relationships across the GCCP family-office matrix; healthcare appetite exists in the universe.
- Ryan/Ralph have proven the Dublin general/cosmetic model works. We replicate the format in regional cities where they are not present, and only enter Dublin on a differentiated sub-specialty axis.
What this is not
- Not a Dublin head-on play against Ryan/Ralph (suicide).
- Not a discount or volume-led model (kills clinical credibility and recapitalisation valuation).
- Not a build-everywhere-fast platform (capital efficiency over speed).
- Not a partner-proximity-driven default to Cork — site selection is data-led across the four cities.
Success definition · 5 years
Two or three dermatology centres operating to the Ryan/Ralph standard across the four target cities, generating recurring AM and equity carry, with a defensible clinical brand and a Phase 2 surgical centre opportunity in development. Platform is recapitalisation-attractive to UK/EU dermatology platform or healthcare PE.
02 · The Proven Model — Institute of Dermatologists
A 6-year-old, founder-led platform compounding from 2,900 sq ft to 40,000 patient visits per year.
IoD is the closest institutional template GCCP has. Their Phase 2 — Surgical Institute Dublin — opens June 2026 and is the timing window that frames the GCCP thesis.
Patient visits / yr
~40k
Confirmed by co-founders, Feb 2026
Estimated revenue
€10–14m
FY26 run-rate
EBITDA margin
25–35%
Estimated, sector-benchmarked
Footprint
~2,900sq ft
10 Pembroke Place, Ballsbridge D4
The model decoded
The Institute runs three distinct revenue streams under one roof — medical dermatology (GP-referred, insurer-billed), a full cosmetic suite (laser, injectables, PRP, microneedling, Ultherapy, body contouring), and a retail skincare product line. ID Formulas — a longevity skincare supplement brand — is the fourth revenue stream, built on the back of clinical brand credibility.
The quality differentiator
All botulinum toxin and dermal filler injections are performed by consultant dermatologists and plastic surgeons only. This is the positioning lever that justifies premium pricing and protects against regulatory risk from unqualified aesthetics practitioners. Credential transparency is the moat against Therapie/Sisu/Sk:n-style chains.
Founder profile · Caitríona Ryan
| Medical degree | UCD — first-class honours, first place in medical class |
|---|---|
| Specialist registrar | St Vincent's University Hospital, Dublin (Dermatology SpR) |
| Residency | Baylor Dermatology Residency Program, Dallas, Texas |
| Faculty post (US) | Vice Chair, Department of Dermatology, Baylor University Medical Center |
| Current academic | Associate Clinical Professor, UCD · Charles Institute of Dermatology |
| Boards | FAAD · FRCPI · International Psoriasis Council · BAD · IAD · BCDG |
| Publications | 70+ peer-reviewed papers (incl. JAMA, Lancet first-author) · Co-edited textbook Psoriasis 2nd ed. (Routledge) |
| Awards | IMAGE PwC Businesswoman of the Year 2025 — Entrepreneur of the Year |
| Media | Pat Kenny Show · Irish Times · IMAGE · own podcast (Dermatology S.O.S.) · 120k Instagram |
The IoD consultant team
| Consultant | Sub-specialty | Other affiliations |
|---|---|---|
| Prof. Caitríona Ryan (co-founder) | Medical & cosmetic, psoriasis, biologics, skin cancer | Blackrock Clinic; UCD Charles Institute |
| Prof. Nicola Ralph (co-founder) | Medical & surgical derm; photodermatology | Mater MUH (runs National Photobiology Unit); Blackrock Health |
| Prof. Eleanor Higgins | Medical & cosmetic — acne, rosacea, eczema, psoriasis | Blackrock Clinic; ex-St John's Institute London; UCD |
| Dr Isabel Haugh | Cosmetic, medical & paediatric (only paeds specialist in team) | Northwestern Feinberg + UT Southwestern fellowships; 400+ citations |
| + ~10 additional consultants | Surgical, Mohs (incoming), connective tissue, hair loss, oculoplastic | Cross-listed at SVUH, Mater Private, Beacon |
Surgical Institute Dublin — IoD Phase 2 (June 2026)
A dedicated Skin and Mohs Surgical Centre opening adjacent to the current clinic. Houses 20+ dermatologists, plastic surgeons, and oculoplastic surgeons working collaboratively under one roof. Built using a physician-investor model with Conor Murphy (also co-founder of ID Formulas) as commercial CEO — Ryan and Ralph lead clinical direction.
"Until recently, only one doctor performed Mohs surgery publicly in Ireland — at St James's, with public patients waiting nine months or more. Bon Secours Cork is the only private Mohs department in the country. The Surgical Institute Dublin is the first standalone private Mohs centre in Dublin."
Ryan / Ralph Competitor Intelligence · Reference Memo
Five lessons GCCP takes from IoD
- Clinical founder + commercial operator as co-founders — Ryan/Ralph (clinical) + Conor Murphy (commercial). This is the structure to replicate.
- Self-funded growth is possible — IoD invested €1.6m in expanded centre of excellence from operating cashflow within ~3 years.
- Consultants don't need to leave hospital posts — Ryan and Ralph remain at Mater / Blackrock alongside running IoD. GCCP's pitch is "build a private practice base alongside" — not "leave your hospital."
- The clinical brand is the moat; ancillary revenue compounds on top — ID Formulas, Surgical Institute, education / training all stack on the IoD halo.
- Don't compete with IoD in Dublin head-on — go where they aren't going: Cork, Galway, regional flagships, sub-specialty differentiation in Dublin only.
03 · National Market Sizing
A €550–700m total economy. A €280–400m private pool. A €60–90m GCCP shot.
Triangulated bottom-up from NCRI, NTPF, HSE, Statista, Euromonitor, and operator-level disclosures. UK per-capita cross-check passes.
Irish dermatology economy — TAM decomposition
FY26 estimate · €m · midpoints
Bottom-up market table
| Metric | FY26 estimate | 5-yr CAGR | Confidence |
|---|---|---|---|
| Total Irish dermatology TAM (services + retail) | €550–700m | 6–8% | Medium |
| Public / HSE spend (incl. biologics, phototherapy, OPD) | €150–200m | 4–5% | High |
| Private dermatology services SAM | €280–400m | 8–10% | Medium |
| GCCP-addressable SOM (multi-specialty centres) | €60–90m | — | Target |
| Adjacent retail (skincare, cosmeceuticals, trials, education) | €280–320m | 9–11% | Medium |
Source: GCCP Strategy bottom-up roll-up · NCRI · NTPF · HSE NSP · Statista · Euromonitor · operator disclosures.
Three takeaways for the platform thesis
The whitest white-space
Skin-cancer screening + surgical dermatology — €20–35m private pool, ~12% CAGR, only one private Mohs centre in Ireland (Bon Secours Cork). GCCP's sharpest entry vector.
The load-bearing wall
Medical dermatology is the most defensible anchor: €70–95m private pool, sticky biologics-eligible cohorts, insurance-reimbursed, low cosmetic-cyclicality. IoD proves €10–14m at 40k visits.
The cash-flow engine
Cosmetic injectables + laser is the largest pool (€170–250m) but the most contested. A consultant-led "medical-grade" position is differentiable; a chain race-to-the-bottom is not.
04 · Supply & Demand Gap
Demand is growing twice as fast as supply.
Per the HIQA April 2026 Health Technology Assessment — the canonical document on the state of Irish dermatology — demand grew 55% from 2019–2024 while WTE consultant supply grew only 28%.
Demand-supply divergence · Irish dermatology · 2019–2025
indexed to 2019 = 100
| Metric | Figure | Date | Source |
|---|---|---|---|
| Patients waiting for consultant dermatologist OPD | >60,000 | Jun 2025 | HIQA HTA Apr 2026 |
| Annual new referrals from primary care | 99,994 | 2024 | HIQA HTA |
| Growth in referrals 2019–2024 | +55% | — | HIQA HTA |
| Growth in WTE consultant supply 2019–2025 | +28% | — | HIQA HTA |
| Patients waiting >12 months | >10,000 | 2023 | AllView / Pharmacy News IE |
| Some patients waiting | up to 3 years | 2025 | HIQA Chief Scientist |
| Completed public OPD appointments per year | ~150,000 | 2024 | HIQA HTA |
| Public ISF benchmark shortfall | ~22% | Apr 2025 | ISF · NCPD |
"There remains an urgent need to recruit more consultant dermatologists."
HIQA Chief Scientist · March 2026
The POCC23 wedge
The Public Only Consultant Contract (effective January 2026) prohibits new POCC23 holders from on-site private practice in public hospitals — 60% of HSE consultants are now on POCC. This systematically channels private caseload into purely private facilities. A decade-long structural tailwind, not a cyclical one.
05 · The Consultant Universe
~80 active consultant dermatologists across the island. The recruitment universe is named, mapped, and reconciled.
Two independent long-list pulls (Perplexity Pro · ChatGPT v2) reconciled to a working universe of 78–85 active practitioners. ~46 in Dublin · ~14 in Cork · ~3 in Galway · ~4 in Limerick/Clare · 2 in Waterford · 12 counties with zero listed.
Active in Ireland
75–95
IMC Specialist Register · active practice
CCT graduates / yr
3–4
~6–8 needed to stand still
HST training posts (RoI)
17
+ 8 in NI · 5-yr programme
Diaspora pool
8–15
UK · AU · US · UAE returner-eligible
Geographic distribution
| City / region | Active consultants | Density per 100k | vs. benchmark (1.0/100k) |
|---|---|---|---|
| Dublin metro (incl. Tallaght, Blackrock) | ~46 | 1.10 | Below benchmark |
| Cork | ~14–15 | 0.51 | Half benchmark |
| Galway | ~3 | 0.36 | ⅓ benchmark |
| Limerick / Clare | ~4 | 0.49 | Half benchmark |
| Waterford | 2 | ~0.5 | Below |
| Kerry | 2–3 | ~0.4 | Below |
| Sligo | 1 | ~0.5 | Below |
| Louth (Drogheda) | 1–2 | ~0.5 | Below |
| Kildare | 1–2 | ~0.5 | Below |
| Belfast / NI | 9–10 | ~0.5 | Below |
| Wexford · Kilkenny · Carlow · Laois · Offaly · Wicklow · Meath · Tipperary | 0 | 0 | ZERO LISTED |
Source: Reconciled long-list — 02_Clinical_Partner_Track/long_list_reconciliation.md · IAD Find-a-Dermatologist register · IMC Specialist Division
The setting split
| Setting | Estimated # | Notes |
|---|---|---|
| HSE primary post (with private off-site rights, legacy contracts) | 55–65 | Type B / C — primary recruitment universe |
| Private-only / predominantly private | 15–25 | IoD, Blackrock Health, Beacon, Bon Secours, Hermitage, regional clinics |
| Recently-returned international / visiting clinical professors | 5–10 | Diaspora signal · Cleveland Clinic / Baylor / NHS / AU |
| Total active | ~75–95 | IMC verification pending |
Recent capacity formation
Time-stamped events that materially change the consultant supply picture:
| Date | Event | Net effect |
|---|---|---|
| Jun 2023 | Aoife Lally's private practice at SVPH closed | Dublin private –1 |
| Jul 2023 | Stephanie Menzies CCT'd; visible across Beacon and IoD | Dublin private +1 |
| Jul 2024 | Kate Lawlor CCT'd; Bon Secours Tralee profile + South Wales appointment | Status unclear · Tralee/Wales |
| 2025 | Niamh Byrne built Dublin private practice at Blackrock — Cambridge-trained, medical + surgical | Dublin private +1 net (premium positioning) |
| 2025 | Dr Isabel Haugh founded Dr Haugh Dermatology & Aesthetics, Adelaide Rd D2 | New Dublin competitor — paediatric & cosmetic |
| Mar 2025 | Lisa Roche re-joined SIVUH (Cork) in permanent consultant role | Cork public +1 |
| Feb 2026 | Cathal O'Connor appointed locum at CUH (London fellowship in genodermatoses + paediatric) | Cork +1 · only post-fellowship paediatric outside Dublin |
Strategically interesting recruitment targets
Cathal O'Connor (Cork, post-London fellowship) and Niamh Byrne (Dublin, Cambridge-trained) are the most strategically interesting net additions. Both Irish-trained, both fresh fellowships, both early-career private positioning. Realistic Stage 2 outreach targets if platform positioning aligns with their sub-specialty.
Recruitment market signals
- Type B / C contract holders are the priority pool. Already split between HSE and private; can be offered rooms-and-platform deal or partner equity without forcing them to leave the HSE.
- Mid-career exits from public posts: anecdotal evidence of frustration with HSE administrative burden, slow consultant-post approvals (IHCA: 142 of 309 vacancies unfilled >12 months), and capped on-site private activity. Several reportedly evaluating private-only.
- Diaspora returners: 8–15 Irish consultants in UK / AU / US / UAE. Returners typically seek (a) equity, (b) lifestyle, (c) school-age family pull. Run structured outreach Q3 2026.
- UK consultants seeking IMC Specialist Division registration: small but growing, especially post-Brexit private-pay friction in London. ~6–12 month registration timeline.
Sourcing channels
- Direct approach via personal network (Ryan, Ralph, IoD alumni, RCPI alumni)
- Targeted LinkedIn outreach (search yields ~60–80 individuals)
- RCPI dermatology trainee committee (Y4–Y5 SpRs approaching CCT)
- Industry-specific recruiters (Global Medics, CSEConnect, Locum Direct)
- UK / AU / US "return to Ireland" career fairs (RCPI hosts annually)
06 · Consultant Economics
Public scale tops at €280k. Private earnings clear €500k. Equity-partner anchors push €900k+.
Total clinical compensation envelope at platform scale (Y5) is estimated at €7.0–8.5m per annum platform-wide — 55–65% consultant draw, 35–45% allied health.
Public scale (HSE 2025/26 POCC pay)
The 2023 Public-Only Contract sets a 6-point scale: €209,915 → €252,150 rising to €280,513 at the top of the post-2025 increased scale (PSA 2024–2026 1% August 2025 uplift; February 2026 adjustments). Add allowances:
- On-call / clinical director / academic uplifts: €10–40k
- Pension (defined-benefit, Single Public Service Pension Scheme for new entrants)
- 30 days annual leave + 11 days study leave
Effective public consultant total package: ~€230k–€310k including allowances and pension value, before any private earnings.
Private earnings benchmarks
| Engagement model | Headline rate | Notes |
|---|---|---|
| Sessional (per 4-hour clinic) | €1,000–€1,800 / session | Self-employed, room+secretarial included; consultant retains receipts less platform fee |
| % of receipts (associate model) | 60–75% to consultant | Industry standard at IoD-style centres; varies with cosmetic vs. medical mix |
| Cosmetic procedural (Botox / filler / laser) | ~70–85% to consultant | Higher because product cost borne by clinic |
| Mohs / surgical day rate | €2,500–€4,000 / day | + procedural fees · supply-constrained specialism |
Indicative private earnings ramp · full-time, mature book
| Stage | Annual earnings |
|---|---|
| Year 1 ramp | €180k–€280k |
| Year 2–3 stabilised | €350k–€500k |
| Mature anchor consultant | €500k–€900k+ |
Total comp by model
| Model | Total comp range | GCCP fit |
|---|---|---|
| Hybrid (HSE base + 2 private days) | €280k–€450k | Sessional contractor in our centre |
| Full-private associate (no HSE) | €350k–€650k | Salaried / % deal, no equity |
| Full-private partner (with platform equity) | €450k–€900k cash + capital event | GCCP target for anchors |
UK comparator
NHS consultant scale 2025: ~£105k–£141k base + Clinical Excellence Awards. Private NHS consultants typically add £150k–£500k+ private. Top London cosmetic dermatologists at sk:n / Cadogan / Harley Street can clear £700k–£1.5m+ all-in. Ireland trades ~10–20% below London for equivalent volume — but with materially lower competition and much shorter waiting lists (a marketing tailwind).
07 · Equity Architecture
Four reference archetypes. One recommended GCCP structure.
Ireland is small enough that 2–3 anchor consultants effectively are the platform. Equity, non-compete, and operational structures must mitigate that key-person exposure.
The four archetypes
7a · Institute of Dermatologists (Dublin)
Model: Consultant-founded centre of excellence combining medical, cosmetic, surgical, skincare. ~14-strong faculty, ~40k patients/year. Co-founders (Ryan, Ralph) hold equity; associates likely on % of receipts.
Lesson: The bullseye comparator. Multi-consultant, partnership-led, US-style centre-of-excellence. Platform value sits with the founders.
7b · sk:n Group (UK · TriSpan PE)
Model: ~70+ clinics, 150+ doctors/consultants, 800 employees. PE-owned platform; consultants employed or contracted, not equity partners. Brand is the asset.
Lesson: The late-stage model. At 2–3 centres GCCP cannot run sk:n economics. Consultants need to feel like owners. Sk:n collapsed July 2024.
7c · Cadogan Clinic (London)
Model: 100+ GMC consultants, multidisciplinary, founder-led. Six consulting rooms + five operating rooms. Consultants self-employed, paying for rooms / theatre time — "platform-as-a-service."
Lesson: Useful flagship template for Dublin 8,000 sqft. Lighter equity but sticky because the infrastructure is hard to replicate.
7d · Schweiger Dermatology (US · LNK Partners)
Model: Roll-up of physician-owned practices. Selling physicians retain equity, receive cash event, continue practising. ~$488m raised; founder still CEO.
Lesson: The "buy-and-roll" model relevant when GCCP hits Y3–Y5 and starts acquiring sub-scale Irish practices.
The recommended GCCP architecture
| Tier | Who | Structure | Equity envelope |
|---|---|---|---|
| Tier 1 · Founding Partners | 2–4 anchor consultants | 5–10% each in OpCo (or HoldCo above OpCo + PropCo) · 4-yr vest, 12-mo cliff, leaver provisions · "eat what you kill" pay (% of receipts) + pro-rata share of platform EBITDA | 10–40% total |
| Tier 2 · Associate Consultants | 4–8 across centres | % of receipts model · no equity at hire · option pool vesting with tenure / performance · non-compete radius (~5–10km, 12 months post-departure) | 5–10% option pool |
| Allied health / non-clinical leadership | Practice managers, RANP leads, marketing | Phantom equity / EBITDA bonus pool | 5–10% |
| Total partner / option envelope | 20–35% of OpCo | ||
Leaving 65–80% to GCCP / LP capital. In line with what private platforms in Ireland will need to give away to anchor genuine clinical talent.
PropCo / OpCo structure
GCCP's preferred wrapper: PropCo holds the building (60–70% GCCP ownership; lets to OpCo on triple-net basis at market rent); OpCo holds the operating clinic (consultant equity sits here, not in PropCo). Triple-net lease aligns clinical performance with property cashflow without dragging GCCP into clinical operations. Mirrors the GCCP hotel operator model.
08 · Allied Health & Staffing Model
A scaled centre is 80% allied-health by headcount. The economics work only if the consultant is the highest-priced clinician.
RANPs, Mohs technicians, and dermatology medical photographers are the three critical scarcity points — likely require active poaching from CHI / Beaumont / SVUH or UK recruitment.
Allied-health roles · supply, comp, training
| Role | IE supply | Training route | Annual comp |
|---|---|---|---|
| Registered Advanced Nurse Practitioner (RANP) — Dermatology | Very scarce — single-figure RANPs nationally | RGN → MSc Advanced Practice (UCC, Galway, TCD) + 500 supervised hrs + NMBI registration | €75–110k base + on-call |
| Clinical Nurse Specialist (CNS) — Dermatology | Modest pool, mostly hospital-employed | RGN + dermatology-specific post-grad; NMBI division | €60–80k |
| Aesthetic / Dermatology Nurse | DANAI-affiliated; growing | RGN + private aesthetics training | €45–65k base + commission |
| Medical Photographer | Very scarce — most are NHS-trained UK | IMI / clinical photography qualifications | €45–55k |
| Mohs Histotechnologist | Almost none private-side; HSE-trained | On-job + IBMS or US-trained | €55–75k |
| Aesthetician / Skin Therapist | Plentiful | CIDESCO / ITEC | €30–45k + commission |
| Patient Coordinator / Reception | Plentiful | None specific | €30–40k |
| Practice Manager (Centre) | Modest | Healthcare ops background | €70–90k |
Per-centre staffing — flagship Dublin (~8,000 sq ft)
6 consulting rooms, 2 procedure rooms, 1 minor-op theatre.
| Role | FTE | Rationale |
|---|---|---|
| Lead Consultant Dermatologist (anchor / founding partner) | 1.0 | Brand anchor, MDT lead, recruitment magnet |
| Associate Consultants | 3–4 | Cover medical, cosmetic, surgical / Mohs, paediatric |
| Visiting / Sessional Consultants | 0.5 | Sub-specialty coverage |
| Registered ANP (Dermatology) | 2 | Triage, reviews, biologics monitoring |
| Clinical Nurse Specialists | 2 | Phototherapy, paediatric eczema, biologics |
| Aesthetic Nurses | 2 | Cosmetic procedural list |
| Medical Photographer | 1 | Mole-mapping, surgical doc, marketing assets |
| Mohs Tech | 1 | Required if Mohs in scope |
| Aestheticians / Therapists | 3 | Skincare and lower-acuity revenue |
| Practice Manager | 1 | Centre P&L, operator interface |
| Patient Coordinators / Reception | 4 | Bookings, billing, insurer reconciliation |
| Marketing / Front-of-house Lead | 1 | Brand, content, cosmetic concierge |
| Total | ~21–24 FTE | Allied health is 80% of headcount |
Per-centre staffing — satellite (~4,000 sq ft)
| Role | FTE |
|---|---|
| Lead Consultant + 1 Associate | 2.0 |
| Visiting Consultants | 0.5 |
| RANP | 1 |
| Aesthetic Nurse + CNS | 2 |
| Aestheticians | 1.5 |
| Practice Manager / Reception / Coordinator | 3 |
| Total | ~10 FTE |
09 · Geographic Opportunity
Outside Dublin, private dermatology supply is genuinely thin.
Stage 1 scope locked to four cities. Site selection is data-led, not partner-proximity-led — Cork is no longer presumed Clinic 1.
| City | Catchment | Private supply today | GCCP working hypothesis | Stage |
|---|---|---|---|---|
| Dublin | 5.2m region | 16 listed private; Ryan/Ralph dominant | Differentiated sub-specialty only — never head-to-head with IoD. Hatch Street as possible pilot. | Stage 1 |
| Cork | ~580k city-region | 3 listed; Bon Secours Mohs, Lee Clinic, Cork Dermatology, Carrigtwohill | Strong narrative (Half Moon Street relationship; thin private supply). Must compete on evidence — no longer presumed Clinic 1. | Stage 1 |
| Waterford | ~120k county | 0 listed | South-East catchment. Open question: standalone vs satellite/visiting-consultant model from Cork or Dublin. | Stage 1 |
| Galway | Connacht catchment | 1 listed; Bon Secours + Galway Clinic present | High-income demographic. Saturation vs. under-served question to resolve. | Stage 1 |
| Limerick | — | 1 listed | Deferred unless surfacing data brings forward. | Phase 2 |
| Belfast | — | 9–10 listed | Cross-border / NI regulatory complexity outside Stage 1 scope. | Phase 2 |
The single sharpest geographic fact
Waterford / Wexford / Kilkenny / Carlow / Laois / Offaly / Kildare / Wicklow / Meath / Tipperary / Clare / Kerry — zero private consultants listed across twelve counties. The supply gap outside the four major cities is acute.
Consultant density per 100k · benchmark vs. actual
County-level consultant density
vs. Comhairle 1-per-100k benchmark
10 · Sub-Sector Decomposition
Fifteen sub-sectors. Three anchors. One race-to-the-bottom to avoid.
The dermatology service universe mapped by scale, saturation, opportunity, margin, and GCCP fit. Sources: GCCP sub-sector primer + market sizing roll-up.
| Sub-sector | IE €m | CAGR | Saturation | Opportunity | EBITDA | GCCP fit |
|---|---|---|---|---|---|---|
| Mohs / surgical dermatology | €15–22m | 10–12% | Critical undersupply | 5/5 | 25–35% | Anchor 1 |
| Medical dermatology | €70–95m | 7–9% | Medium | 5/5 | 25–35% | Anchor 2 |
| Skin cancer screening / mole mapping | €8–14m | 11–13% | Low | 5/5 | 30–40% | Anchor 3 |
| Cosmetic / consultant-led (Tier A) | €120–170m | 9–12% | Low at Tier A | High | 25–40% | Margin layer |
| Laser & light-based | €50–80m | 8–10% | Medium | Medium | 20–30% | Stack |
| Biologics / advanced systemic therapy | €10–20m+ | 12–15% | Very low (private) | High | 25–35% | Stage 1 |
| Phototherapy / PDT | €2–5m | 4–6% | Very low (private) | Medium-High | 25–35% | M/L scenario |
| Patch testing / contact | €3–7m | 5–7% | Low | Medium | 25–35% | Bundle |
| Teledermatology | €2–5m | 20–25% | High (AllView) | Medium | 15–25% | Partner |
| Trichology / hair restoration | €15–25m | 9–11% | Low-Medium | Medium-High | 25–45% | Stage 2 |
| Paediatric dermatology | €5–9m | 6–8% | Low | Medium | 15–25% | Stage 2 |
| Occupational dermatology | €8–15m | 6–8% | Low | Medium | 25–35% | B2B wedge |
| Cosmetic-only (Tier D — Therapie/Sisu) | €120–170m | 9–12% | Very high | 1/5 | 15–25% | AVOID |
| Skincare retail / DTC | €10–20m | 10–13% | Low at consultant tier | Brand layer | 15–25% | Stage 3+ |
| Vulval & genital dermatology | Niche | — | Very low | Credibility | 25–35% | Bundle |
Source: 09_Reference/02_Dermatology_Sub_Sector_Primer.md · research/02_market_sizing_subsectors.md
11 · White-Space Map
The institutional, multi-specialty, consultant-led centre is a white-space of one in Ireland today.
With IoD's Surgical Institute opening June 2026, the market is moving from a zero to a one. GCCP's window to be the second-and-third institutional centre is open today and likely closes within 18–30 months.
| Sub-sector | Demand intensity | Current supply | White-space |
|---|---|---|---|
| Mohs micrographic surgery | High (>13k NMSC/yr) | 1 private centre (Bon Secours) + St James's public | 5/5 — RED HOT |
| Multi-specialty institutional centres | High | IoD only (and IoD Surgical Institute opens June '26) | 5/5 — GCCP THESIS |
| Total-body AI-assisted mole mapping | High and rising | 3–4 dedicated private clinics | 4/5 |
| Consultant-led teledermatology (premium tier) | High (HSE waitlist 60k+) | 1–2 active operators (DermView, Vhi360) | 4/5 |
| HS / autoimmune sub-specialty private clinic | Moderate (1% prevalence ~54k pts) | Effectively zero dedicated private | 4/5 |
| Paediatric atopic dermatitis private centre | High (15% childhood AD) | None at scale (CHI dominates public) | 3/5 |
12 · Operator Landscape
40+ private dermatology operators across the island. Three competitive registers.
The market bifurcates: institutional consultant-led centres at the top (IoD, Blackrock, Mater Private, Belfast Skin); volume cosmetic chains at the bottom (Therapie, Sisu, the now-defunct Sk:n); and a wide middle of solo / small-group consultant practices. Source: research/03_competitive_landscape_ireland.md.
Geographic capacity heat-map · sub-sector × city
| Region | Medical Derm | Surgical / Mohs | Cosmetic | Paediatric | Capacity grade |
|---|---|---|---|---|---|
| Dublin (D2/D4) | Heavy — IoD, Beacon, Mater Private, SVPH, Blackrock | Strong — Ormond, Murad, Coleman, Adare | Heavy & crowded — Ailesbury, Adare, BFD, Eden, River Medical, Renaissance, Sk:n legacy | Thin — covered ad-hoc by Beacon, OLCHC consultants in private rooms | A− |
| Dublin (West / Hermitage) | Light | Light | Light | None | C |
| Cork | Moderate — Bon Secours, Lee Clinic, Mater Private Cork, UPMC Cork | Moderate — Lee Clinic Mohs, Bon Secours | Crowded (Therapie, River, Ailesbury Cork) | Lee Clinic offers paeds | B |
| Galway | Moderate — Galway Clinic, Bon Secours, Blackrock Health | Light | Moderate (Galway Skin, Kelly Clinic) | None notable | C+ |
| Limerick | Light — Bon Secours, Blackrock Health | Very light | Light | None | C |
| Waterford | Light — UPMC Whitfield (Rose Clinic) | Light | Very light | None | D |
| Belfast | Strong — Belfast Skin, Kingsbridge, Cathedral, Ulster Independent, Claro | Strong — Mohs at Belfast Skin, Kerr at Kingsbridge | Strong | Belfast Skin notable for paeds | B+ |
| Derry / NW | Light — Kingsbridge North West | Very light | Light | None | D |
| Kilkenny / Carlow / Wexford | Visiting clinics only | None notable | Light | None | D |
Strategic read
The medical and paediatric dermatology white-space is in Dublin's western/southern fringe, in Limerick, in Waterford, and outside the M50 generally. Cosmetic is saturated in Dublin and Cork — entering on cosmetic alone is a price-war strategy.
Tier-1 institutional operators · master table
Operators of scale, with at least one IMC-registered specialist consultant dermatologist on staff. Revenue and EBITDA are estimates per research/03 methodology unless a CRO/Companies House figure is cited.
| Name | City | Lead consultant(s) | FTE | Rev €m [est.] | EBITDA% [est.] | Notes |
|---|---|---|---|---|---|---|
| Institute of Dermatologists | Dublin (Pembroke Pl, D4) | Ryan, Ralph, Higgins, Verma | 5–6 | 7–9 | 25–32% | ANCHOR BENCHMARK |
| Blackrock Clinic — Dermatology | Dublin (Blackrock) | Ryan, Higgins, Coleman, Ormond, Salim, Condon | 6–8 | 6–8 | n/m (hospital) | Single largest concentration of senior derm consultants in ROI |
| Mater Private Dermatology | Dublin (Eccles St) | Murad, Keane, Storan + visiting | 4–5 | 3–4 | n/m | Skin-cancer / Mohs strength · InfraVia portfolio |
| Beacon Hospital — Derm Dept | Dublin (Sandyford) | Ahmadi + 2 visiting | 3 | 3–4 | n/m | Hospital outpatient model |
| St Vincent's Private — Derm | Dublin (Elm Park) | A. Ryan + 4 others | 5 | 2.5–3.5 | n/m | Charitable; public-private hybrid |
| Restorative Dermatology (Coleman) | Dublin (within Blackrock) | Rosemary Coleman | 1 | 1.4–1.8 | 30–38% | High-margin solo · own skincare line |
| Adare Clinic | Dublin (Clare St D2) | Multi-consultant + nurses | 2–3 | 2–3 | 18–24% | Hybrid medical-cosmetic; multi-site |
| Ailesbury Clinic | Dublin (Clonskeagh D4) | Treacy, de Klerk, Divya | 3–4 | 4–6 | 15–22% | Strongest cosmetic-derm brand · Cork sister site |
| Beacon Face & Dermatology (BFD) | Dublin (Beacon) | Patrick Treacy & team | 1.5 | 1.5–2.5 | 18–24% | Cosmetic-heavy |
| Skin & Hair Clinic (Murad) | Dublin (Eccles St) | Aizuri Murad | 1 | 1.0–1.5 | 28–35% | Murad's own private rooms · platform-anchor candidate |
| Dr Haugh Dermatology | Dublin (Adelaide Rd D2) | Isabel Haugh | 1 | recent (2025) | est. 30%+ | New competitor · paediatric & cosmetic |
| Eleanor Higgins Cosmetic Derm | Dublin (within IoD/Blackrock) | Higgins | 1 | 0.8–1.2 | 32–40% | Personal brand; high-margin solo |
| Hermitage Medical — Derm | Dublin (Lucan) | Visiting (rota) | 1.5 | 1.0–1.5 | n/m | Underweight on derm vs other Blackrock Health sites · West Dublin whitespace |
| Bon Secours Cork — Derm | Cork (College Rd) | Molloy, Fahy + visiting · Mohs (only private in IE) | 3 | 2–3 | n/m | Largest Cork private derm hub · Mohs anchor |
| Lee Clinic Dermatology | Cork (Lee Rd) | O'Connor, Gibson + others | 3–4 | 2.5–3.5 | 28–34% | HIGHEST-QUALITY ACQUISITION TARGET · Mohs + paediatric |
| Mater Private Cork — Derm | Cork | Sally O'Shea + others | 2 | 1.0–1.5 | n/m | Smaller but growing footprint |
| Galway Clinic — Derm | Galway (Doughiska) | Markham, Shaikh + visiting | 2–3 | 1.5–2.5 | n/m | Hospital-resident dermatologists |
| Perfect Skin (Shaikh) | Galway (within Galway Clinic) | Taj Shaikh | 1 | 0.9–1.3 | 30–38% | Acquisition target candidate |
| UPMC Whitfield (Rose Clinic) | Waterford (Cork Rd) | Visiting consultants | 1 | 0.8–1.3 | n/m | Single private hospital in SE region |
| Belfast Skin Clinic | Belfast (Lisburn Rd) | Multiple — derm, plastics, allergy, paeds | 4–6 | 4–6 | 22–30% | BEST NI MEDICAL-DERM CLINIC · partnership candidate |
| Cathedral Dermatology | Belfast | Consultant derm + plastic surgeons | 2–3 | 1.0–1.6 | 24–30% | Consultant-led |
| Kingsbridge Private Hospital — Derm | Belfast + Sligo + NW | Murphy, Kerr (visiting), others | 3 | 2–3 | n/m | 3fivetwo Healthcare Group |
| Ulster Independent Clinic — Derm | Belfast (Stranmillis) | Kerr + visiting | 2–3 | 1.3–2.0 | n/m | Long-established consultant venue (1947) |
| Claro Skin Clinic | Belfast | Olga Kerr | 1 | 0.9–1.3 | 30–35% | Kerr is one of NI's few Mohs-trained dermatologists |
Volume cosmetic chains · adjacent, not direct competitors
| Name | Footprint | Model | Status / signal |
|---|---|---|---|
| Therapie Clinic | 30+ ROI sites · 100+ all-Ireland | Doctor + nurse network · no consultant derm · volume cosmetic | Group revenue €60–90m all-Ireland · 200k+ Instagram · partnership / referral candidate, not derm competitor |
| Sisu Clinic | 24–25 sites IE/UK/US | Digital-native aesthetic · doctor-led | $20.5m revenue · 47% YoY growth · VC-backed |
| Sk:n Clinics | — | — | CEASED TRADING JUL 2024 · TriSpan PE roll-up failure · cautionary tale |
| River Medical | Dublin / Cork / Belfast | Plastic surgery + aesthetics | €4–7m group rev · adjacent, not direct |
| The Skin Nurse | Dublin | Nurse prescriber-led | Award-winning · strong social |
| Eden Medical / ClearSkin / Refine / ORA / Amara / Glow / SkinGlow | Dublin (multiple) | Aesthetic / cosmetic doctor-led | ~€0.2–2.5m each · long tail |
Acquisition targets · ranked
- Lee Clinic Dermatology (Cork) — €2.5–3.5m revenue, 28–34% EBITDA, Mohs + paediatric capability. The single highest-quality independent private derm acquisition target in Ireland.
- Belfast Skin Clinic — €4–6m revenue, multi-specialty (derm + plastics + allergy + paeds), founder-led. Strongest NI partnership / acquisition opportunity. Cross-border patient flow already exists.
- Perfect Skin (Shaikh, Galway) — €0.9–1.3m solo specialist; could become a Galway anchor with operator support.
- Skin & Hair Clinic (Murad, Dublin) — Murad's own rooms; pre-cursor to potential platform anchor if recruited as Tier-1 founding partner.
13 · Pricing & Service Mix
Three price tiers operate. The opportunity is at the top with selected insurer rails.
Most consultant-led clinics do not publish transparent menus — pricing is verbal on enquiry or buried in FAQ pages. The aesthetic chains are the opposite: aggressive online price advertising. This bifurcation is the strategic opportunity for GCCP. Source: research/09_service_mix_pricing.md.
The three price tiers
| Tier | Positioning | Initial consult | Examples |
|---|---|---|---|
| Premium / Consultant-led | Specialist register dermatologist · Ballsbridge / D2 / D4 / Beacon Suite · low patient volume · high price | €250–€500 | Institute of Dermatologists, HRBR, Beacon Face & Dermatology, Dr Haugh, Dr Morrow |
| Hybrid / Hospital-private | Consultant-led inside private hospital · insurer rails · mid-volume | €180–€280 | Beacon Hospital, Mater Private, Blackrock Health, Hermitage, Galway Clinic, UPMC |
| Value / Aesthetic chain | Nurse / GP / cosmetic-doctor led · high volume · retail format | €0–€149 (often free consult) | Sk:n (defunct), Thérapie, Sisu, Laser + Skin Clinics |
GCCP positioning recommendation
Premium with selected insurer rails — an Institute-of-Dermatologists-class medical brand at the top of the funnel, with a deliberately curated cosmetic and skincare wing that picks off Beacon-style hybrid revenue without diluting the brand. Higher capex / higher fit-out / higher EBITDA-margin model than a Sk:n-style chain — and more defensible against consolidator entry.
Headline economics · modelled
| Metric | Premium | Hybrid |
|---|---|---|
| Blended revenue per consultant 4-hour session | €1,950–€2,650 | €1,250–€1,650 |
| Revenue per consult room per day (10-hr window) | €2,800–€4,800 | €1,800–€3,000 |
| Revenue per consult room per year (220 trading days) | €620k–€1.05m | €395k–€660k |
| Revenue per sq ft (well-utilised, ~3,000 sq ft) | €2,000–€3,200 | €1,300–€2,000 |
Indicative pricing · core medical services
| Service | Range | Premium ceiling |
|---|---|---|
| Consultant initial consultation (medical) | €250–€500 | €500 (HRBR senior) |
| Follow-up consultation | €150–€250 | €220 |
| Paediatric dermatology consultation | €250–€350 | €350 |
| Mole check / single spot | €70–€150 | €150 |
| Full-body skin cancer screening | €180–€300 | €300 |
| Mole mapping — FotoFinder ATBM full-body | €350–€495 | €495 (Molescan, River Medical) |
| Mole mapping — annual rescan (yr 2+) | €250–€325 | €325 |
| Skin biopsy — punch (incl. histology) | €120–€350 | €350 |
| Excisional surgery — benign / suspect lesion | €400–€1,400 | €1,400 (theatre + histology) |
| Mohs first stage | €1,400–€2,400 | €2,400 (Belfast Skin comparator) |
| Mohs additional stage | €600–€900 | — |
| Mohs reconstruction (per defect) | €800–€2,500 | — |
| Cryotherapy — first lesion | €80–€150 | €150 |
| Patch testing — full European baseline + extended | €350–€550 | €550 |
| Phototherapy UVB course (24 sessions) | €1,400–€1,900 | €1,900 |
| Photodynamic therapy (PDT) — face/scalp two-session protocol | €1,200–€1,800 | €1,800 |
| Biologics — clinic-led monitoring package (annual, 4 visits) | €600–€900 | €900 |
Indicative pricing · cosmetic / aesthetic
| Service | Volume chain | Premium consultant |
|---|---|---|
| Botox — 1 area | €149 (Thérapie women) | €300 (Ailesbury / IoD) |
| Botox — 3 areas | €350 | €450–€550 |
| Hyperhidrosis — both axillae (W) | €550–€650 | €600–€700 |
| Dermal filler — per ml | €295 (Thérapie) | €350–€550 |
| Tear-trough filler | — | €450–€650 (premium-only — high-skill) |
| Microneedling — single session | €180–€220 | €250–€295 |
| RF microneedling (Secret Pro / Morpheus8) | €700–€950 | €1,200–€1,500 |
| Chemical peel — superficial | €130–€195 | €150–€225 |
| Chemical peel — medium TCA 15–25% | €295–€395 | €395–€495 |
| Laser hair removal — face (course of 6) | €375–€450 | €595–€750 |
| Laser hair removal — full body (course of 6) | €1,250–€2,000 | €2,000–€2,800 |
| Vascular laser — course of 3 (rosacea) | €595–€795 | €995–€1,250 |
| Fractional CO₂ — full face | €1,500 | €1,800–€2,500 |
| Acne treatment package (3 months · consult + 3 peels + topical) | €595–€795 | €795–€995 |
Margin profile by service
- Highest gross margin: mole mapping (≈82%) · package memberships (≈75%) · aesthetic injectables (≈68%) · skincare retail (≈42% gross / 30% net of staff)
- Lowest gross margin: biologics admin (≈25% — drug pass-through is near-zero margin) · Mohs surgery (≈30% net of theatre/histology) · patch testing (≈40%)
VAT note: cosmetic procedures are 23% VAT-able; medical procedures (incl. biopsy, screening, cryotherapy of pre-cancerous lesions, consultant-billed medical care) are VAT-exempt.
14 · Institute of Dermatologists — Tier A flagship
The institutional template GCCP mirrors.AI-DRAFT
A 6-year-old Ryan/Ralph platform — facility Ltd + per-consultant ULCs + specialty SPVs — operating at 40k visits/year with €1.6m capex disclosed and a 20-year lease at 10 Pembroke Place. SID surgical centre opens June 2026.
Patient throughput
40k/ year
EE479 podcast, 19 Feb 2026
Disclosed capex
€1.6m
Centre-of-excellence expansion · Business Post 2025
Named consultants
13
IoD team page · 26 LinkedIn employees
Joint corporate entities
6
Facility + ID Skincare + SID HoldCo + SID OpCo + 2 personal ULCs
"PRIMARY BENCHMARK — the single closest institutional template for the GCCP private dermatology platform."
Case Study #1 · IC-pack position
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Seven-entity Ryan/Ralph empire mapped | Facility Ltd (CRO 638541) + 2 personal ULCs + IDI Skincare + Surgical Suite Holdings + SID Healthcare. All four joint entities have Ryan + Ralph as co-directors; Conor Murphy NOT visible as director on free CRO data. |
| Mohs supply moat wider than IoD marketing implies | Lee Clinic Cork already has a dedicated Mohs theatre; Dr Moran already operates Mohs at IoD itself. Total Irish-island operator set = 7–8, not the 4 IoD's "first multidisciplinary" claim implies. |
| €1.6m capex + 20-yr lease = institutional commitment depth | The underwriting anchor for any GCCP Dublin flagship. The IoD founders considered this institutional spend depth necessary; GCCP should plan for similar. |
Strategic implications for GCCP
- Mirror the IoD corporate structure. Per-consultant ULCs + facility Limited + specialty HoldCos. Confirmed as outlier vs Lee, Adare, Beacon — the sophistication is the deliberate platform-readiness signal.
- The Mohs/skin-cancer market gap is larger than IoD's marketing implies. GCCP's surgical strategy should not assume IoD has locked the market.
- Surgical Institute Dublin (June 2026) is the live competitive event. The window to position before SID launches is now.
- Insurer recognition mechanics need paid confirmation. If panel is per-consultant via ULC, GCCP's PropCo/OpCo/clinical-partner structure works cleanly.
- BSHS confirms the standalone template, not equity-JV. IoD's structure (facility-Ltd + per-consultant ULC + specialty SPVs at separate addresses) is the institutional template; GCCP should mirror it exactly.
Pending paid pulls: ~€55 · See research/case_studies/01_Institute_of_Dermatologists/
15 · Lee Clinic Dermatology, Cork — Tier A regional, #1 acquisition target
The southern complement to a Dublin platform.AI-DRAFT
Dual-founder Mayo+ABD+FACMS practice, 24 years operating, founders aged 61–62, the only dedicated private Mohs department in Ireland — and an unexpected freehold-developer layer surfaced by OSINT.
Founder ages
61–62
Succession window aligned with 5-yr GCCP horizon
Estimated revenue
€2.5–3.5m
2 FTE × €1.25–1.75m × medical/surgical premium
Estimated EBITDA
€0.7–1.2m
28–34% multi-consultant medical-derm benchmark
Indicative EV
€4.5–8.5m
6–8× EBITDA · excl. freehold layer
"The cleanest available real-world anchor for the T2-A 'Boutique medical-led' cell in our 9-cell scoring matrix — real-world validation that T2-A targets are achievable in Ireland."
Case Study #2 · Position in GCCP thesis
Three findings that change the analysis
| Finding | Detail |
|---|---|
| O'Connor is a freehold developer-shareholder | Via Lee Clinic Management Company Ltd (CRO 479681) — alongside 4 other Cork consultants. Oct 2021 estate sale process at €6m guide / 6% yield — outcome NOT YET VERIFIED. Dual-layer deal architecture (OpCo + RE) now live. |
| Only dedicated private Mohs department in Ireland | O'Connor brings Mayo + ABD + FACMS — unique credential combination in Irish private market. Other 6–7 operators all work sessional or public-anchored. |
| Single-Limited OpCo · pre-deal restructure required | No HoldCo, no ULCs, no skincare/retail arm — NOT IoD-style multi-entity. Pre-close: insert HoldCo above OpCo, carve out personal-services ULCs, register brand IP at IPOI as Day-1 post-close (~4–6 months). |
Strategic implications for GCCP
- Dual-layer deal architecture. Not just consultant practice purchase — PropCo participation is potentially live via the OMC freehold layer.
- Pre-deal restructuring required (~4–6 months). Single-Ltd must be re-cast before close.
- Warm-intro only. Not a banker call — UCC Medicine / Mayo Clinic alumni / RCPI fellowship / Bon Secours Cork executive channels.
- Lee Clinic is the southern complement to a Dublin platform. Not competitor to IoD/SID — north–south complementary pair, with Bon Secours Cork as existing surgical anchor.
- GCCP brand opportunity is enormous. Zero digital footprint today — rebrand + structured booking + insurer-portal recognition lifts patient capture without touching clinical quality.
Pending paid pulls: ~€34 · See research/case_studies/02_Lee_Clinic_Dermatology/
16 · Therapie Clinic — Tier D archetype (comparator only)
Why GCCP does not consolidate the volume aesthetic chains.AI-DRAFT
Ireland's largest cosmetic-aesthetic chain — 35 island-of-Ireland sites, >€100m group revenue at 2022, family-controlled via PMG Capital. Studied as a comparator, not an acquisition target.
Sites · Ireland
35
RoI ~31 + NI 4 at Jan 2026 · ~80–85 globally
All-Ireland revenue (FY24 est)
€70–100m
Group >€100m at 2022 (+54% YoY)
Through-cycle EBITDA margin
8–14%
Volume aesthetic benchmark · Sk:n comp
Specialist Register dermatologists
0
IAD + IMC cross-check
"A high-volume, doctor-supervised aesthetic-retail platform — not a clinical specialist asset; rolling it up would import retail-property liability, a sub-15% margin base, regulatory tail-risk under the Patient Safety Bill, a 12% 1-star service-quality tail, and a clinical workforce structurally incompatible with a Tier A consultant-led dermatology platform."
Case Study #3 · IC-pack one-liner verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| "Post-2024 ownership consolidation" DISPUTED | The 2024 event was founder Paul McGlade's death (12 Aug 2024, aged 69), NOT a PE transaction. Group remains family-owned via PMG Capital. €30m debt facility (Q4 2022) is bank, not PE. Sons Phillip (CEO) and Katie operate; 2021 board professionalisation reads as sale-prep, not sale completion. |
| Pure expansion mode · not consolidation | 10 site openings, ZERO closures 2024–Jan 2026. The 65-clinic expansion was announced 5 days after Sk:n's UK collapse — opportunistic capture of the Sk:n vacuum. Not the right window for Tier D consolidation. |
| Adare is the singular Tier D upgrade-risk | Dr Naomi Mackle is on the IMC Specialist Register with H.Dip Dermatology — Adare opened a Chelsea (London) site in 2025. No other Tier D operator has crossed that line. Track Bill commencement as the leading Tier D consolidation indicator. |
Strategic implications for GCCP
- The IC-pack answer is now defensible. 7-factor structured rebuttal to the "why not Tier D?" question is deployment-ready.
- Patient Safety Bill exposure is the unhedged Tier D risk. No consultation submission, no medical-director appointment, no Specialist Register hire 2024–2026 — most informative signal in the case.
- McGlade vendor profile is sale-prep, not sale-active. Window may open 2026–2028 but is not open today.
- Cost-discipline data point. Therapie at 8–14% margin × ~€100m revenue = €8–14m EBITDA × 4–7× (Sk:n distress) = €30–100m EV. Tier A operators at €10m × 30% × 6–8× = €18–24m EV — quality-adjusted Tier A is dramatically cheaper per unit of clinical authority.
- Adare needs separate case study treatment (see Section 20) — singular Tier D operator with a Specialist Register MD.
Pending paid pulls: ~€8.50 · See research/case_studies/03_Therapie_Clinic_Tier_D/
17 · Ailesbury Clinic — Tier C archetype (comparator only)
A "Cosmetic Dermatology" brand making a claim it cannot defend on credentials.AI-DRAFT
Strongest doctor-led cosmetic-derm brand in the Republic, 24+ years operating — and the canonical Tier C archetype. Studied as a comparator, not an acquisition target.
Years operating
24+
Founded 2002 (Dublin); Cork ~2005
IMC Specialist Register · derm
0
None of 5 named clinicians · zero IAD-listed
Estimated revenue
€4–6m
Working-knowledge — UNVERIFIED
Estimated EBITDA margin
15–22%
Mixed cosmetic benchmark · implied €0.6–1.3m
"A celebrity-doctor-led, cash-pay cosmetic chain marketed under a 'Cosmetic Dermatology' brand it cannot defend on credentials — and therefore fails the Tier A test on workforce, brand transferability, service-mix, and key-person concentration."
Case Study #4 · IC-pack one-liner verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Brand-claim vs credential gap is the central Tier C vulnerability | Website tagline "Skin, Laser & Cosmetic Dermatology" + dedicated /dermatology1/ page listing BCC, melanoma, SCC, Bowen's, mole screening — yet zero IMC Specialist Register derms, zero IAD-listed. Highest credential = RCPI Professional Diploma / PG Dip. Under the Patient Safety (Licensing) Bill 2025 this is a genuine regulatory-tail vulnerability. |
| Treacy ≠ BFD · correction | REFUTED — HIGH confidence. BFD was founded 2006 by Mr Kambiz Golchin (ENT/facial plastic surgeon), acquired by CPP Europe May 2025. Treacy has no publicly disclosed BFD link. |
| CPP Europe is the relevant Tier C buyer | CPP's structural play (retain founder-clinician, build cap table around them, batch with UK targets) fits Ailesbury's profile precisely. GCCP would be competing with CPP for Tier C assets — and likely losing on price. |
Strategic implications for GCCP
- IC-pack Tier C answer is now defensible. Credential-gap argument is sharper than the Therapie version because Ailesbury is making a Cosmetic Dermatology claim, not a pure aesthetic one.
- Adare needs urgent case study attention as the structural twin and the verified upgrade-mover (see Section 20).
- Credential-gap vulnerability is universal across Tier C — Ailesbury, Eden, ClearSkin, Refine. GCCP's Tier A premium is exactly the gap; this becomes a positive selling point for institutional capital.
- Treacy succession risk is severe. Founder = brand. Ageing-founder Tier C operators are CPP's entry point, NOT GCCP's Tier A platform thesis.
- CPP Europe and GCCP play different games. CPP rolls up Tier C; GCCP plays Tier A. Two non-competing strategies in the same market.
Pending paid pulls: ~€16 · See research/case_studies/04_Ailesbury_Clinic_Tier_C/
18 · Dr Benvon Moran — Mohs partnership target (consultant case)
The only un-claimed FACMS Mohs consultant in Dublin private practice.AI-DRAFT
First time GCCP analysis treats a consultant as the unit of investment, not a clinic. Tests whether a partnership could build a national Mohs network without GCCP owning clinics.
Active sites
4
Hermitage · Blackrock · IoD · St James's
Mohs cases / year (est)
250–450
Session-day count × ACMS norms
Credentials
FACMS
UBC Vancouver fellowship · TCD Clin Assoc Prof
Career stage
~44–46
Peak earning window · ~20 yrs to retirement
"VIABLE — CONTINGENT on SID directorship resolution. Recommended approach: staged Sessional Acquisition (Q3 2026) → Munster Mohs SPV (2027)."
Case Study #5 · GCCP-partnership verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Moran NOT visibly captured by SID | SID PR consistently names founders (Ryan + Ralph + Murphy as CEO) but NOT the "20 consultants in equity raise". Moran is listed on IoD's team page but never flagged for SID. The absence is signal — she is the highest-value un-claimed Mohs Specialist Register + FACMS consultant in Dublin. Competitive vulnerability for SID. |
| Shared admin spine reveals Blackrock as anchor | Same secretary and @blackrockhealth.com email across IoD and Blackrock pages. Blackrock is Moran's administrative home base. Any partnership conversation opens via the Blackrock admin spine, NOT via IoD (Ryan/Ralph are SID-conflicted). |
| Munster is the strategic opening | All 4 sites are Dublin despite UCC origin. Munster and Connacht are Mohs white-space — Lee Clinic is the only private dedicated department but no Mohs flagship outside Cork city. Cork acquisition + Limerick / Mid-West Moran venue = complementary, not exclusive. |
Strategic implications for GCCP
- Moran is the partnership target. O'Connor is locked to Lee Clinic; Ormond and Barry are St James's-anchored. Moran is the only un-claimed FACMS Mohs consultant in Ireland.
- The Munster Mohs SPV is a clean white-space play — cannot be built by IoD (Dublin-locked), Lee Clinic (capacity-constrained), or CPP/Therapie (no Mohs capability).
- The €7 paid CRO pull on SID HoldCo + OpCo is the single highest-strategic-value spend in the entire GCCP project — it determines whether Moran is available.
- The 12-month window is closing. If GCCP does not move on Moran by Q3 2026, another player (CPP Europe expansion, Bupa/TDP entry) may lock her up.
- Stage 2 (Munster Mohs SPV) has long-term synergy with the Lee Clinic Cork acquisition — Lee Clinic in Cork city + GCCP-Moran in Limerick/Mid-West covers Munster Mohs supply for at least 5 years.
Pending paid pulls: ~€13 · See research/case_studies/05_Dr_Benvon_Moran_Mohs_Partnership/
19 · Belfast Skin Clinic — Tier A NI flagship (first cross-border target)
The first verified-financials Tier A operator in the GCCP library.AI-DRAFT
NI Companies House delivered 3 years of filed accounts at zero cost. Triangulated £1.0–1.4m EBITDA on £4–6m revenue / 22–28% margin — first defensible IC-pack number for an Irish-island Tier A outside UK comps.
Revenue (triangulated)
£4–6m
Corp-tax accrual ÷ 25% UK CT
EBITDA (triangulated)
£1.0–1.4m
22–28% margin · audit-exempt FY21–FY25
Avg employees · FY25
55
Up from 34 (FY22) · 5 consultant hires 2024–25
Founder · Medical Director
~64
Dr Pamela McHenry · sole founder DOB Jul 1961
"VIABLE acquisition target — CONTINGENT on Kingsbridge competing-acquirer scenario AND on McHenry succession plan."
Case Study #6 · IC-pack one-liner verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Finance Act 2024 participation exemption | Effective 1 Jan 2025 — Ireland exempts dividends from EU/EEA/treaty-partner subsidiaries; UK qualifies. Dublin HoldCo + UK/NI OpCo (5%+ holding for 12+ months) → UK dividends to ROI HoldCo are FULLY EXEMPT from Irish CT. ~25% blended effective rate, no upstream leakage. |
| Kingsbridge / Exponent £300m EV (Aug 2024) is the most important M&A datapoint in the project | Exponent acquired Kingsbridge Healthcare Group (4 hospitals, 11 medical centres, 400+ consultants) — Lisburn Road flagship is minutes from BSC's Deramore Drive. High-likelihood competing acquirer with capital firepower and the consultant-pipeline playbook. |
| Corp-tax-accrual triangulation = methodology breakthrough | £237k FY24 corp-tax ÷ 25% UK CT = ~£950k PBT → +D&A = ~£1.0m EBITDA. Apply retroactively to IoD (CRO 638541) and Lee Clinic (CRO 451594) to yield first verified Irish-side Tier A EBITDA numbers. |
Strategic implications for GCCP
- BSC is the cleanest cross-border target in the library. Verified financials, single-founder cap table, purpose-built freehold via Muldoon Family Pension SIPP, Mohs genuinely in-house (McKenna + Dolan), sale-prep posture clear (Apr-May 2025 recap + 2 new directors Nov 2025 / Mar 2026).
- Kingsbridge is the competing acquirer to beat. GCCP must compete on move-faster, cleaner-structure, or better cross-border narrative — not price-equivalent synergies.
- Kill the cross-border insurance reimbursement assumption. Post-Brexit, VHI/Laya/ILH do NOT routinely reimburse UK private consultants. ROI patient mix = self-pay + NIPHS overflow, NOT in-network referrals.
- Mohs operator set is wider than prior thinking — adding McKenna + Dolan (BSC) + Kerr (Claro) means Irish-island private Mohs = 7–8 operators. Genuine gap is regional Munster/Connacht.
- Founder concentration is the single biggest deal-architecture risk. McHenry = entire brand at ~64. Any transaction must include 5-year clinical commitment + non-compete + designated MD-successor handover.
Pending paid pulls: ~£10–£20 · See research/case_studies/06_Belfast_Skin_Clinic_NI_Flagship/
20 · The Adare Clinic — tier-mover hypothesis test
Tier C+ with a verified UK door — but no credentialling upgrade.AI-DRAFT
Tests the load-bearing question that six prior case studies flagged: can Tier C operators graduate to Tier B in Ireland through credentialling alone? The HYBRID verdict closes Tier-C/D positioning for the IC pack.
Sites (incl. Chelsea)
3
Limerick V94 · Dublin 2 · 18 Park Walk SW10
IAD-listed clinicians
0
Mackle = IMC GENERAL PRACTICE · Penev · Jansen
Triangulated group revenue FY25
€2.0–3.5m
UK FRS 105 cap + 3-site benchmark + headcount
Nov 2024 recruitment outcome
18mo+
No new clinician through May 2026
"Adare is 'Tier C+ with a verified UK door.' It has solved the geographic-distribution problem but not the credentialling problem. CPP Europe picked Beacon (Golchin, maxillofacial) over Adare in Dublin — a peer-validated read on where Adare actually sits in the consolidation order."
Case Study #7 · IC-pack one-liner verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Mackle's IMC division is GENERAL PRACTICE — verbatim from her own bio | "Specialist Division — General Practice" — NOT Dermatology. Cardiff Diploma 2008 is a PG H.Dip; does NOT route to Specialist Register Derm. NOT on the IAD "Find a Dermatologist" register. REFUTED — Adare is Tier C with better marketing. |
| Chelsea opening is REAL · verified through five independent registers | UK CH 15427637 (inc 19 Jan 2024); CQC location 1-23290319695 (registered 26 May 2025); trading site adaredermatology.co.uk; UK landline; Patient.info listing. Sharp contrast with Ailesbury's UNVERIFIED Chelsea claim. Bootstrapped — £100 share capital, zero charges, £43k negative equity. GCCP would be first institutional money in. |
| Nov 2024 recruitment failure = cleanest evidence of supply constraint | Adare advertised for a consultant dermatologist in Nov 2024. 18 months later, no new clinician on team page, no IAD-listed clinician on staff. Even Ireland's most credible Tier C upgrade-mover with a fresh UK platform couldn't recruit within an 18-month window. Cleanest evidence the Specialist Register supply constraint protects GCCP's Tier A premium. |
Strategic implications for GCCP
- Adare is NOT a GCCP target. Credentialling refute + GP-route MD + founder concentration + no insurer panels rule it out structurally.
- Adare IS useful as a comparator — the canonical "Tier C with verified UK expansion" that proves geographic distribution alone does not constitute Tier B status.
- The CPP Europe parallel is the strongest IC-pack framing. CPP rolls up Tier C; GCCP plays Tier A. Two non-competing strategies in the same market.
- The Nov 2024 recruitment failure is the headline structural-protection argument — cite prominently in the IC pack.
- Watch the 12 Sep 2025 PSC restructure for follow-on activity. Quarterly Companies House check; trigger paid pull on any subsequent share allotment or director appointment.
Pending paid pulls: ~€42 · See research/case_studies/07_Adare_Clinic_Tier_Mover/
21 · Bon Secours Cork — hospital-department comparator
The hospital-JV question, answered definitively across all six Irish private hospital groups.AI-DRAFT
Tests: could GCCP partner with a hospital instead of building? The verdict is clear: NOT THE DOMINANT STRATEGY. The live Irish precedent (CPPE/BFD May 2025) is consultant-led standalone + hospital-campus tenancy.
Group revenue FY24
€478.8m
+10.1% YoY · BSMH US parent post-2019
Cork standalone (est)
€175–195m
37% × group · 300–344 beds · 1,600+ staff
Cork derm dept (est)
€2–4m
Only branded private Mohs dept in Ireland (Cork CCC)
Hospital groups screened
6 / 6
Mater · Beacon · Blackrock · UPMC · SVPH · BSHS
"Hospital-JV is structurally improbable across all six Irish private hospital groups; the live Irish precedent (CPPE/BFD May 2025) is consultant-led standalone + hospital-campus tenancy. The Lee Clinic Mohs arrangement at BSHS Cork is the operating template — fee-for-service, not equity."
Case Study #8 · IC-pack one-liner verdict
Three findings that change the analysis
| Finding | Detail |
|---|---|
| Hospital business model is SPLIT, not "the hospital model" | Inpatient + day-case = direct-billed by hospital to insurer (the hospital model). Outpatient consultations = fees set by individual consultant, charged independently of hospital (the standalone-clinic model). The "hospital model" advantage applies cleanly only to day-case revenue. |
| "Charity blocks a JV" is empirically wrong | BSHS has done TWO for-profit JVs with CCPC clearance: UPMC Ireland (2016, M/16/055) and Alliance Medical / Barringtons MRI (2021, M/21/037). Institutional-capital posture exists; the question is structural fit and mandate, not ability to transact. |
| No specialty-line equity JV has ever transacted in Ireland | Confirmed across all six Irish private hospital groups. Even Mater Private under InfraVia (sophisticated infra owner since 2018) has chosen integrated growth over JV. The live Irish model is CPPE/BFD May 2025 — specialty operator on hospital campus, NOT equity JV. |
Strategic implications for GCCP
- The hospital-JV question is now definitively answered. Equity JV across all six groups is structurally improbable. Fee-for-service / theatre-licensing IS viable (BSHS already does it with Lee Clinic for Mohs).
- Lee Clinic Mohs at BSHS Cork is the operating template GCCP should replicate. Not equity. Fee-for-service.
- Mater Private remains the most plausible Phase-2 acquirer at exit. InfraVia's 2018 entry + 7–10yr infra hold = 2025–2028 exit window.
- Beacon under Macquarie (Feb 2024, €342m) is the second Phase-2 watchlist item. Tolerated BFD speciality tenant — could become receptive to a GCCP minority equity proposal in 2026–27.
- Three brief-premise corrections for IC housekeeping — BSMH US parent (not standalone Sisters); Tralee 1921 ground-up (not Mount Alvernia); BSHS has done two for-profit JVs.
Pending paid pulls: ~€30 + free pulls · See research/case_studies/08_Bon_Secours_Cork_Hospital_Comparator/
22 · Cross-Case Strategic Findings
All eight case studies converge on the same structural conclusion.AI-DRAFT
Tier A is genuinely defensible in Ireland because the Specialist Register dermatology supply pool cannot be scale-recruited. The remaining strategic architecture follows from that one fact.
Tier framework — conclusive view after 8 case studies
| Tier | Archetype | Real-world examples | GCCP plays here? |
|---|---|---|---|
| A | Specialist Register-led, insurer-funded, multi-consultant | IoD (#1), Lee Clinic (#2), BSC (#6) + Moran (#5) specialty-franchise | YES — primary thesis |
| B | Spec Reg with strong cosmetic | Does not exist in Ireland as a graduated archetype | n/a |
| C | Doctor-led aesthetic, NOT Spec Reg | Ailesbury (#4), Adare (#7), Eden, ClearSkin, Refine, BFD (CPP-owned) | NO — CPP Europe's territory |
| D | Volume aesthetic chain (nurse / therapist-led) | Therapie (#3), River Medical, Renaissance | NO — Sk:n cautionary tale |
Six deployable IC-pack one-liners
Q · Why not Tier D?
"A high-volume, doctor-supervised aesthetic-retail platform — not a clinical specialist asset; rolling it up would import retail-property liability, a sub-15% margin base, regulatory tail-risk under the Patient Safety Bill, and a clinical workforce structurally incompatible with a Tier A platform."
Q · Why not Tier C?
"Ailesbury is a celebrity-doctor-led, cash-pay cosmetic chain marketed under a 'Cosmetic Dermatology' brand it cannot defend on credentials — and therefore fails the Tier A test on workforce, brand transferability, service-mix, and key-person concentration."
Q · Why not the upgrade-mover (Tier C+)?
"Adare is 'Tier C+ with a verified UK door.' It has solved the geographic-distribution problem but not the credentialling problem. CPP Europe picked Beacon (Golchin, maxillofacial) over Adare in Dublin — a peer-validated read on where Adare actually sits."
Q · Why is GCCP's Tier A premium structurally protected?
"Adare advertised for a consultant dermatologist in November 2024. 18 months later, no new clinician on team page, no IAD-listed clinician on staff. Even Ireland's most credible Tier C upgrade-mover couldn't recruit a Specialist-Register dermatologist within an 18-month window."
Q · Where does GCCP play vs CPP Europe?
"Two non-competing strategies in the same market. CPP plays Tier C — doctor-led, cosmetic-anchored, founder-retention. GCCP plays Tier A — Specialist Register, insurer-funded, flagship-medical. Different price discipline, different exit profile."
Q · Why standalone clinic, not hospital JV?
"Hospital-JV is structurally improbable across all six Irish private hospital groups; the live Irish precedent (CPPE/BFD May 2025) is consultant-led standalone + hospital-campus tenancy. Lee Clinic Mohs at BSHS Cork is the operating template — fee-for-service, not equity."
JV-Receptivity Scorecard — all six Irish private hospital groups
| Group | Equity JV | Fee-for-service | Rationale |
|---|---|---|---|
| Mater Private | 4 / 10 LOW–MED | 7 / 10 | InfraVia (2018) — integrated growth not JV |
| Beacon (Macquarie) | 5 / 10 MED | 8 / 10 | New owner Feb 2024; tolerated BFD speciality tenant; too early to read |
| Blackrock Health | 3 / 10 LOW | 6 / 10 | Goodman family; €500m programme owner-funded |
| UPMC Ireland | 3 / 10 LOW | 5 / 10 | Burned by Beacon 2008–14 (€20m exit cost) |
| St Vincent's Private | 2 / 10 LOW | 5 / 10 | Charity + NMH governance turbulence |
| BSHS | 2 / 10 | 8 / 10 | Equity JV improbable; fee-for-service / theatre-licensing works (Lee Clinic Mohs precedent) |
Mohs operator set — corrected to 7–8 island-wide
| # | Operator | Site(s) | Fellowship | FACMS | Dedicated theatre? |
|---|---|---|---|---|---|
| 1 | Dr William ("Billy") O'Connor | Bon Secours Cork + Lee Clinic | Mayo Clinic | YES | Yes — only private Mohs dept in Ireland |
| 2 | Dr Benvon Moran | Hermitage + Blackrock + IoD + St James's | UBC Vancouver | YES | No (sessional) |
| 3 | Prof Patrick Ormond | St James's HSE + Hermitage + Blackrock private | Royal Victoria Newcastle | No | Yes (HSE St James's founder) |
| 4 | Dr Rupert Barry | St James's HSE + St James's Private | Royal Victoria Newcastle | No | Yes (St James's public) |
| 5 | Dr John McKenna | Belfast Skin Clinic + Belfast HSC Trust | Guy's & St Thomas | YES (BSDS) | Yes (in-clinic Mohs lab) |
| 6 | Dr Olivia Dolan | Belfast Skin Clinic + RVH Belfast Trust | U Michigan | YES | Yes (in-clinic Mohs lab) |
| 7 | Dr Olga Kerr | Claro Skin Clinic + Kingsbridge + UIC (Belfast) | Mohs-trained · spec TBC | TBC | No |
| 8 | Dr Aizuri Murad | Beacon + Bloom House (Dublin) | Cleveland Clinic procedural derm | No | No |
Density ~1.4 per million population (vs UK 1.5/m, US 6.6/m). All 8 operators concentrated in Dublin + Cork city + Belfast — Limerick / Mid-West / Connacht / Border counties remain genuine Mohs white-space.
Irish / NI healthcare PE comp set · 2018–2025
| Date | Acquirer | Target | EV | Sector |
|---|---|---|---|---|
| Aug 2024 | Exponent Private Equity | Kingsbridge Healthcare Group (NI) | £300m / €355m | Multi-specialty private hospital |
| Dec 2024 | Bupa Health Services | The Dermatology Partnership / Stratum (UK) | Est. 10–14× EBITDA | Dermatology |
| Apr 2024 | Macquarie Asset Management | Beacon Hospital (Dublin) | ~€342m | Multi-specialty private hospital |
| 2018 | InfraVia | Mater Private Network (IE) | ~€500m / $578m | Multi-specialty private hospital |
| May 2025 | CPP Europe | Beacon Face & Dermatology (Dublin + Tralee) | Not disclosed | Tier C cosmetic-derm |
GCCP's Tier A platform thesis at 2–3 sites / €15–25m revenue / €4–7m EBITDA × 9–13× = €36–91m EV sits comfortably below institutional appetite but at attractive sub-scale risk-adjusted return.
Total project diligence cost · paid pulls
~€220 across the 8 case studies closes 80%+ of remaining gaps. Highest-strategic-value spend: €7 SID HoldCo + OpCo B1s (Case #5) — determines whether Moran is available, which determines whether the partnership thesis is viable.
23 · The 9-Cell Tier Matrix
Three tiers. Three divisions. Nine cells. One top-scored model.
Each cell scored across seven dimensions — profitability, scalability, capital efficiency, OpCo/PropCo capability, complexity inverse, founder-time inverse, and risk-adjusted return — totalling 100 points.
Division A · Medical
Division B · Cosmetic
Division C · Surgical / Skin Cancer
Tier 1
€100k–€1m
€100k–€1m
T1-B
Chambers + 1 device
T1-C
Screening only (no Mohs)
Tier 2
€500k–€4m
€500k–€4m
T2-A
Boutique medical-led
T2-B
Boutique cosmetic + medical
T2-C
Day-surgery + TBI (no Mohs)
Tier 3
€8m–€50m+
€8m–€50m+
T3-A
Multi-site GP-referrer
T3-B
Premium hub + chain
T3-C
Mohs flagship + biologics + paeds
Top three by total score
| Rank | Cell | Full name | Score | Capex | Y5 revenue | EBITDA | Y5 EV | EV/Capex |
|---|---|---|---|---|---|---|---|---|
| 1 | T2-B | Tier 2 Cosmetic Boutique with medical mix | 78.4 | €2.0m | €5.8m | €1.91m / 33% | €22m | 11.0× |
| 2 | T3-B | Tier 3 Cosmetic Premium Hub + Skin Clinics Chain | 78.2 | €15m | €22m | €7.7m / 35% | €92m | 6.1× |
| 3 | T2-A | Tier 2 Medical Boutique | 69.7 | €1.8m | €5.5m | €1.49m / 27% | €16m | 8.9× |
The headline finding
Cosmetic division (B) dominates the scoring across all three tiers. Cosmetic boutique single-clinic (T2-B) is the highest-scoring single cell — highest-margin cash-pay revenue, scalable, lighter regulatory burden than surgical-Mohs, strong capital efficiency. The instinct toward Mohs flagship as the "gold standard" is correct on prestige but wrong on risk-adjusted return at GCCP's capital and time-budget envelope.
"No financial model survives a consultant-supply failure."
Master Overview · Section 0 · Three findings
24 · Tier Economics
Capital envelopes, revenue paths, and exit values by tier.
Mid-point figures from the GCCP Dermatology Tier Comparison Model (10-tab Excel). Sensitivity analysis available in the source file.
TIER 1 · €100k–€1m
Sole-consultant chambers
Sessional · 1–2 rooms
Capex
~€0.5m
Y5 Revenue
€1.5m
EBITDA %
22%
Y5 EV
€3.5m
Lowest capital, lowest scaling potential. Defensible only as a network (T1-Net) under a Dublin shared-services hub.
TIER 2 · €500k–€4m
Boutique flagship
Top-scored model · T2-B
Capex
€2.0m
Y5 Revenue
€5.8m
EBITDA %
33%
Y5 EV
€22m
Best risk-adjusted return per the master scoring. EV/Capex 11.0× — highest capital efficiency in the matrix.
TIER 3 · €8m–€50m+
Institutional flagship
Multi-site or Mohs hub
Capex
€15m
Y5 Revenue
€22m
EBITDA %
35%
Y5 EV
€92m
Highest absolute return but highest binding constraint on consultant supply (7–10 consultants). Phase 2/3 progression after T2 proves out.
EV/Capex efficiency by tier · Y5
multiple of invested capital · midpoints
25 · Capex & Unit Economics — Deep Dive
Flagship €17.4m. Satellite €7.4m. Platform IRR 17.5–20% unlevered, 25–29% equity at scale.
Bottom-up unit economics for a flagship Dublin centre, a satellite, and a 3-centre rollout. Triangulated against UK / US listed and PE-disclosed comparators (sk:n, Cadogan, Schweiger, Forefront, Anne Arundel). Source: research/08_capex_opex_unit_economics.md.
Headline platform economics
| Metric | Flagship Dublin (8,000 sq ft) | Satellite (4,000 sq ft) | Platform · 3 centres · 5 yrs |
|---|---|---|---|
| Total all-in capex | €15.5–19.4m | €6.5–8.3m | €29.0–36.5m cumulative |
| Mid-point capex | €17.4m | €7.4m | €32.5m |
| Steady-state revenue (Y3+) | €8.5–10.5m | €4.5–5.5m | €18–22m |
| Steady-state EBITDA margin | 30–34% | 26–30% | 29–32% blended |
| Steady-state EBITDA per centre | €2.7–3.4m | €1.2–1.5m | €5.0–6.3m platform |
| Breakeven revenue per centre | €5.9m | €3.1m | n/a |
| Cash payback (project) | 5.0–5.7 yrs | 5.5–6.2 yrs | n/a |
| Project IRR (unlevered, 10-yr DCF) | 17.5–20.0% | 14.5–17.0% | n/a |
| Equity IRR (60% senior debt, post-SLB exit) | 24–28% | 21–24% | 25–29% platform |
| 10-yr terminal value (8.5× EBITDA mid) | €25–28m | €11–12m | n/a |
Headline call
The unit economics support a multi-billion EBITDA-multiple-grade exit if the flagship clears 80%+ utilisation by Y3 and the consultant fee % stays disciplined at 60–65%. A €17.4m flagship spend produces a €3.0m steady-state EBITDA centre that would be valued at €25–28m on UK healthcare REIT comps alone, before any platform premium. The single largest sensitivity is consultant fee %: a 200 bps shift moves EBITDA margin by c. 4 points and equity IRR by c. 350 bps.
Flagship Dublin · capex breakdown (8,000 sq ft)
Building / shell acquisition + works
| Line | Unit cost | Volume | Low (€000) | High (€000) |
|---|---|---|---|---|
| Shell acquisition (vacant Grade B office, D4) | €600–750/sq ft | 8,000 | 4,800 | 6,000 |
| Stamp duty + acquisition costs | 7.5% | — | 360 | 450 |
| Strip-out and CAT A reinstatement | €55–70/sq ft | 8,000 | 440 | 560 |
| Medical CAT B fit-out (partitions, finishes, joinery) | €275–355/sq ft | 8,000 | 2,200 | 2,840 |
| M&E uplift (HVAC, HEPA, isolated medical earth, UPS) | €180–230/sq ft | 8,000 | 1,440 | 1,840 |
| FF&E (chairs, joinery, signage, art) | — | — | 380 | 470 |
| Sub-total: building | 9,620 | 12,160 | ||
Medical equipment (itemised)
| Equipment | Vendor | Qty | Low (€000) | High (€000) |
|---|---|---|---|---|
| Alex / Nd:YAG laser | Candela GentleMax Pro Plus | 1 | 110 | 150 |
| Picosecond laser | Cynosure PicoSure / Lutronic PicoPlus | 1 | 130 | 170 |
| Q-switched Nd:YAG | Lutronic Spectra | 1 | 80 | 110 |
| CO₂ fractional / ablative | Lumenis UltraPulse / DEKA SmartXide | 1 | 95 | 130 |
| IPL platform | Lumenis M22 / Cynosure Icon | 1 | 60 | 85 |
| Pulsed-dye vascular laser | Candela Vbeam Prima | 1 | 95 | 125 |
| Total body imaging (FotoFinder ATBM) | FotoFinder Systems | 1 | 60 | 85 |
| Hand-held dermoscopes | FotoFinder handyscope / Heine NC2 | 8 | 32 | 48 |
| Electrosurgery | Bovie A1250U / hyfrecator | 3 | 18 | 30 |
| Cryotherapy | CryoPen / Brymill CRY-AC | 2 | 8 | 16 |
| Mohs cryostat | Leica CM1860 / Sakura Tissue-Tek | 1 | 40 | 55 |
| Mohs microscope + bench | Olympus BX46 + grossing station | 1 | 35 | 50 |
| Mohs lab fit-out | Embedding, staining, ventilation | 1 | 60 | 90 |
| Phototherapy cabinet (UVB-NB) | Daavlin / Waldmann | 1 | 45 | 65 |
| PUVA / hand-foot phototherapy | Waldmann | 1 | 18 | 25 |
| Examination chairs / procedure beds | Midmark / Schmitz | 12 | 72 | 108 |
| Sterilisation (autoclave, UWC) | W&H / Melag | 1 | 35 | 50 |
| High-frequency ultrasound | DUB SkinScanner | 1 | 55 | 85 |
| Patch-test station + reagents | Chemotechnique / SmartPractice | 1 | 15 | 22 |
| Sub-total: medical equipment | 1,063 | 1,499 | ||
IT / EMR / digital infrastructure
| Line | Low (€000) | High (€000) |
|---|---|---|
| EMR licence + implementation (HealthOne / Helix / Socrates / ClinicSoftware) | 90 | 140 |
| PACS / image management (FotoFinder Universe) | 55 | 80 |
| Telephony + cloud comms (RingCentral / 8x8) | 25 | 40 |
| Cyber + endpoint protection (Microsoft Defender E5 + Mimecast) | 18 | 28 |
| Patient portal + online booking (Heydoc / Pabau) | 22 | 35 |
| Hardware (laptops, tablets, scanners, printers · 25-user) | 35 | 55 |
| Network / structured cabling (Cat6A + WPA3) | 45 | 65 |
| Sub-total: IT | 290 | 443 |
Soft costs + working capital
| Line | Low (€000) | High (€000) |
|---|---|---|
| Brand identity, photography, web build | 90 | 140 |
| Pre-opening + Y1 launch marketing | 220 | 320 |
| Professional fees (architect, M&E, QS, planning, legal · 10%) | 1,140 | 1,460 |
| Contingency (project · 7.5%) | 850 | 1,090 |
| Working capital reserve (3 months opex) | 700 | 800 |
| Sub-total: soft + WC | 3,000 | 3,810 |
Flagship total · all-in
| Block | Low (€000) | High (€000) | Mid (€000) |
|---|---|---|---|
| Building | 9,620 | 12,160 | 10,890 |
| Medical equipment | 1,063 | 1,499 | 1,281 |
| IT | 290 | 443 | 367 |
| Soft + WC | 3,000 | 3,810 | 3,405 |
| Flagship all-in | 13,973 | 17,912 | 15,943 |
| Per sq ft (all-in) | €1,747 | €2,239 | €1,993 |
| Recommended underwriting target | €15.5–18.5m | €17.0m for IC | |
PropCo / OpCo allocation: PropCo carries shell + stamp + CAT A + structural M&E (~€10.0–12.5m mid); OpCo carries medical CAT B + medical equipment + IT + FF&E + WC (~€5.5–6.0m mid).
Flagship capex composition · midpoint allocation
€15.94m · 8,000 sq ft Dublin flagship
26 · Real Estate Clusters
Six clinical real-estate clusters across the island. Each maps to a distinct tier, brand, and consultant pool.
Site selection follows the consultant-supply and demand-gap evidence — never the inverse. Memos in 03_Real_Estate/ cover Dublin, Cork, Waterford, and Galway in full.
Dublin · 1.1 — D2 / D4 / Ballsbridge corridor
The Harley Street of Dublin. Rents €450–700/sq m; consultant rooms at Pembroke Place command €1,500–2,500/month for half-day sessions. Institute of Dermatologists is the strategic anchor of this cluster — founder-owned, purpose-built. Adare Clinic on Clare Street, Eleanor Higgins, Restorative Dermatology, River Medical, and Eden Medical occupy adjacent blocks.
- Anchor properties: 10 Pembroke Place (IoD, ~2,900 sq ft), Wellington Road, Clare Street, Pembroke Road, Northumberland Road
- GCCP fit: T2-B boutique cosmetic + medical, or T3 flagship (Surgical Institute Dublin sets the precedent)
- Constraint: Direct competition with IoD if positioned as multi-specialty. Differentiate or stay out.
Dublin · 1.2 — Sandyford / Beacon
South-Dublin counterpoint to Ballsbridge. Beacon Medical Group provides infrastructure that few standalones can match — theatre access, imaging, pathology. Cosmetic supply is heavy (Beacon Face & Dermatology, Beacon Consultants Clinic, ClearSkin, ORA).
- Anchor properties: Beacon South Quarter, Beacon consulting suites
- GCCP fit: Sessional rooms within Beacon Hospital ecosystem (lower capex, faster ramp); or boutique medical-derm at perimeter
Dublin · 1.3 — Blackrock / Booterstown
Operationally the densest dermatology venue in ROI — Blackrock Clinic alone hosts 6+ derm consultants (Ryan, Higgins, Coleman, Ormond, Salim, Condon). However the consultants are individually private — there is no single "Blackrock Dermatology" group entity to acquire; you would buy practices one at a time.
Dublin · 1.4 — Hermitage / West Dublin
Lucan / Liffey Valley catchment ≈350k+, materially under-served. Hermitage Medical Clinic runs a light derm offering. This is Dublin's structural whitespace.
- GCCP fit: T2-B or satellite. Lower rent envelope; demand evidence strong (HSE waitlists in West Dublin highest in metro)
Dublin · 1.5 — Mater / D7
Mater Private Network on Eccles St; Skin & Hair Clinic (Aizuri Murad) at Bloom House on the same block; St James's catchment overlap (Ormond). Skin-cancer / Mohs concentration is here.
Cork — College Rd / South Mall + Lee Rd
The only credible secondary-city medical-dermatology cluster. Lee Clinic Dermatology (Lee Road) is the standout independent — Mohs + paediatric capability, €2.5–3.5m revenue, founder-owned, prime acquisition target. Bon Secours College Road runs Ireland's only private Mohs department. UPMC Cork is a new entrant building.
- Anchor properties: Half Moon Street relationship, Princes Street, South Mall, College Road, Lee Road
- GCCP fit: T1 storefront (HALO-fit) on Princes Street; T2 boutique on South Mall; T3 surgical hub adjacent to Bon Secours referral pipeline
- Shell pricing: €460–600/sq ft (Cork city centre)
Galway — Doughiska + Salthill
Galway Clinic at Doughiska (Markham, Shaikh) and Bon Secours Galway run hospital-resident derm models. Perfect Skin (Shaikh's solo practice within Galway Clinic) is an acquisition candidate. Highest-income demographic outside Dublin; MedTech corporate PHI corridor; 15–18 month public derm waits — worst in IE.
- Anchor properties: Doughiska / Galway Clinic adjacency; Salthill / Knocknacarra approach for modern fit-out
- GCCP fit: T2-A medical boutique (HELIX-fit clinical-modern) anchoring biologics + medical derm
- Shell pricing: €420–550/sq ft
Belfast — Lisburn Rd corridor + Stranmillis
Cross-border demand is high — Northern Irish patients already cross the border for private healthcare. Belfast Skin Clinic (Lisburn Rd, multi-specialty), Cathedral Dermatology, Kingsbridge Private Hospital, Ulster Independent Clinic (Stranmillis), Claro Skin Clinic (Kerr's Mohs work), and Marlborough Clinic are the institutional spine. Estimated £25–35m derm-aesthetics combined throughput.
- GCCP fit: Partnership / acquisition with Belfast Skin Clinic likely the most efficient NI entry — already multi-specialty, already founder-led, cross-border patient flow already exists
- Status: Phase 2 in current scope (cross-border / NI regulatory complexity)
Waterford — UPMC Whitfield
Single private hospital in the SE region. UPMC Whitfield (Cork Rd) hosts Rose Clinic; visiting consultants only.
- GCCP fit: T1 satellite from Cork or Dublin · visiting-consultant model · 1,500–3,000 sq ft
City summary table
| City | Indicative footprint | Shell €/sq ft | Status | Stage |
|---|---|---|---|---|
| Dublin | 3,000–8,000 sq ft | €600–750 | Survey complete · 6 sub-clusters mapped | Stage 1 |
| Cork | 2,500–5,000 sq ft | €460–600 | Survey complete · Half Moon St relationship · Lee Clinic acquisition target | Stage 1 |
| Waterford | 1,500–3,000 sq ft | €350–500 | Survey complete · standalone vs. satellite TBD | Stage 1 |
| Galway | 2,500–4,000 sq ft | €420–550 | Survey complete · MedTech corridor | Stage 1 |
| Belfast | 3,000–5,000 sq ft | £500–650 | Acquisition / partnership scoping | Phase 2 |
| Limerick | — | — | Deferred unless surfacing data brings forward | Phase 2 |
PropCo / OpCo structure
GCCP funds and builds medical-grade real estate (PropCo); consultants partner via OpCo equity, analogous to the GCCP hotel operator model. Triple-net lease structure aligns clinical performance with property cashflow without dragging GCCP into clinical operations.
27 · Regulatory Trajectory
HIQA scope is widening. Discipline now is moat later.
Forthcoming Patient Safety (Licensing) Bill 2025 will favour disciplined operators that build to standards before they are required. The window for prudent build-out is open.
| Activity | HIQA registrable today | Trajectory |
|---|---|---|
| Private hospitals (inpatient/day-case surgical derm) | Yes | Status quo |
| Private hospitals (OPD consultant derm) | Yes (Sept 2024) | Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 |
| Standalone outpatient clinics | Light-touch | Patient Safety (Licensing) Bill 2025 incoming |
| Cosmetic-only nurse/GP-led clinics | Light-touch | Material credential and licensing exposure |
Defensive playbook
- Consultant-led, fellowship-trained across every clinical division — credential transparency is the moat.
- Build to private-hospital infection control and clinical governance standards from day one — not retrofit.
- Insurer participation: dual VHI + ILH; hold Laya at non-participating to preserve M&A optionality.
- Document everything: patient pathways, consent, complications, outcome metrics. The audit trail is the recapitalisation asset.
28 · Exit Thesis
8–12× EBITDA. Validated by UK/EU comparables. No equivalent IE platform yet exists.
August Equity's The Dermatology Partnership (9 clinics, 50+ consultants) was acquired by Bupa Health Services in December 2024 — the clearest validation of the insurer-as-platform model.
| Comparable | Geography | Scale | Multiple | Acquirer / outcome |
|---|---|---|---|---|
| The Dermatology Partnership | UK | 9 clinics, 50+ consultants | undisclosed (8–12×) | Bupa Health Services · Dec 2024 |
| Sk:n Group (TriSpan) | UK | ~95 sites · peak £90–110m | collapse Jul 2024 | Cosmetic-only failure mode |
| Sisu Clinic | IE/UK/US | 24–25 clinics · $20.5m revenue | VC-backed · 47% YoY | Aesthetic-only growth play |
| Laya Healthcare | IE | — | 11× P/E | AXA · €650m · 2023 |
Probable acquirer ranking
- Laya Healthcare (AXA) — 45–55% probability per P4 verified. Explicit margin-recapture mandate. Hold non-participating to preserve optionality.
- UK platform consolidator (Bupa, post-Dermatology-Partnership integration; or PE-backed UK derm rollup) — 25–35%.
- Pan-European healthcare PE (CVC, EQT, Apax mid-market) — 15–25%.
- VHI / ILH (state-linked) — <10%; structural acquirer of last resort.
Exit target window
Years 5–7 from Stage 1 capital deployment. Recapitalisation-attractive once two operating centres are at maturity (€20–30m run-rate revenue, 25–35% EBITDA margin) with Phase 2 surgical centre in development.
29 · Decision Log
What we've decided. Why. When.
Canonical record of strategic decisions on the dermatology thesis. Source: 08_Decision_Log/decisions.md.
| Date | Decision | Rationale |
|---|---|---|
| 2026-04-25 | Geographic scope locked to four cities (Dublin, Cork, Waterford, Galway). | Limerick / Belfast deferred to Phase 2 — surfacing data does not yet justify Stage 1 inclusion. |
| 2026-04-25 | Cork no longer presumed Clinic 1. | Site selection is data-led, not partner-proximity-led. Half Moon Street narrative is one signal among several; must compete with the other three cities on evidence. |
| 2026-04-25 | Tier 2 boutique (T2) is the working primary model. | Top-scored cell on the 9-cell matrix (78.4 / 100); EV/Capex 11.0× highest in matrix; capital envelope fits a 2-3 centre platform thesis. |
| 2026-05-01 | Hold Laya at non-participating provider status. | Preserve M&A optionality. AXA's 2023 acquisition of Laya was explicit margin-recapture; becoming a fee-capped Laya provider destroys exit value. |
| 2026-05-07 | Cosmetic-only Tier D model rejected as GCCP path. | Sk:n collapse July 2024 illustrates the structural fragility. Credential transparency is the moat against Therapie/Sisu — not price. |
30 · Open Questions
What we still need to resolve before IC-grade conviction.
Source: 08_Decision_Log/open_questions.md. These five questions block IC presentation; each has an owner and a target resolution path.
| # | Question | Why it matters | Path to resolution |
|---|---|---|---|
| Q1 | Which clinical partner anchors Clinic 1? | No financial model survives consultant-supply failure. The first consultant must be locked before site closes. | Direct outreach · Type B holders · 6–8 named candidates |
| Q2 | Which property type for Clinic 1 (boutique medical-led vs. cosmetic-led)? | Drives capex envelope (€1.8m vs. €2.0m), revenue mix, and consultant brief. | Site shortlist + consultant brief alignment by Q3 2026 |
| Q3 | Product strategy — own retail brand vs. partner SkinCeuticals/ZO? | 15–25% of Y5 revenue at 50–65% gross. ID Formulas (Q1 2026 launch) is the IE precedent. | Decision deferrable to Y2; not gating Stage 1 |
| Q4 | Cork vs. Galway — which city for Clinic 1? | Different anchor logic: surgical anchor → Cork (Bon Secours pipeline); recurring medical anchor → Galway (cleaner unit econ + worst public waits). | P5 county heatmap + consultant availability data + IC discussion |
| Q5 | OpCo equity % for clinical partners? | Recruitment competitiveness vs. dilution discipline. | Term-sheet drafting · benchmark vs. UK platform comparables |
Grand Canal Capital Partners | Confidential | Internal Only
Source-of-truth: GCCP_REPOS/GCCP Dermatology MASTER/ · Companion: Master Overview Deck